Highlights of This Issue 5369

SPECIAL FEATURES

5371 Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer Juliann Chmielecki and William Pao See article p. 5489

Molecular Pathways

5374 Target of Rapamycin Signaling in Leukemia and Lymphoma Collin Vu and David A. Fruman

Special Report

5381 Phase III Clinical Trial Development: A Process of Chutes and Ladders David M. Dilts, Steven K. Cheng, Joshua S. Crites, Alan B. Sandler, and James H. Doroshow See article p. 5557

HUMAN CANCER BIOLOGY

5390 Hypoexpression and Epigenetic Regulation of Candidate Tumor Suppressor Gene CADM-2 in Human Prostate Cancer Guimin Chang, Shuping Xu, Rajiv Dhir, Uma Chandran, Denise S. O'Keefe, Norman M. Greenberg, and Jeffrey R. Gingrich

5402 MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer Maria Dolores Giráldez, Francesc Balaguer, Luis Bujanda, Miriam Cuatrecasas, Jenifer Muñoz, Virginia Alonso-Espinaco, Mikel Lazzabal, Anna Petit, Victoria Gonzalez, Teresa Ocaña, Leticia Moreira, José María Enríquez-Navascués, C. Richard Boland, Ajay Goel, Antoni Castells, and Sergi Castellvi-Bel


CANCER THERAPY: PRECLINICAL

5424 Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia Nicolas Chapuis, Jerome Tamburini, Alexa S. Green, Christine Vignon, Valerie Bardet, Aymeric Neyret, Melanie Pannetier, Lise Willems, Sophie Park, Alexandre Macone, Sauveur-Michel Maira, Norbert Ifrah, François Dreyfus, Olivier Herault, Catherine Laccombe, Patrick Mayeux, and Didier Bouscary

5436 The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models Sara A. Flanigan, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, Aik Choon Tan, Andrew Thorburn, and Stephen Leong

5447 Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity Robert J. Kinders, Melinda Hollingshead, Scott Lawrence, Jiuping Ji, Brian Tabb, William M. Bonner, Yves Pommier, Larry Rubinstein, Yvonne A. Evrard, Ralph E. Parchment, Joseph Tomaszewski, and James H. Doroshow; for the National Cancer Institute Phase 0 Clinical Trials Team
Overexpression of High-Mobility Group Box 2 Is Associated with Tumor Aggressiveness and Prognosis of Hepatocellular Carcinoma
Jung-Hee Kwon, Jongmin Kim, Jin Young Park, Sun Mi Hong, Chang Wook Park, Seek Joo Hong, Sun Young Park, Yoon Jung Choi, In-Gu Do, Jae-Won Joh, Dae Shick Kim, and Kwan Yong Choi

Prognostic Significance of RNA-Dependent Protein Kinase on Non–Small Cell Lung Cancer Patients
Abujiang Pataer, Maria Gabriela Raso, Arlene M. Correa, Carmen Behrens, Koji Tsuta, Luisa Solis, Bingliang Fang, Jack A. Roth, Ignacio I. Wistuba, and Stephen G. Swisher

Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma
Lydia Kriegl, Andreas Jung, Jutta Engel, Rene Jackstadt, Christiane J. Bruns, Frank T. Kolligs, Thomas Kirchner, Burkhard Göke, and Enrico N. De Toni

Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, John A. Thompson, Piotr Tomczak, Cezary Szczylik, Mike McDonald, Sarah Eastty, William H. Shingler, Jackie de Belin, Madusha Goonewardena, Stuart Naylor, and Richard Harrop

A Randomized Trial of Ex vivo CD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival
A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies
Steven K. Cheng, Mary S. Dietrich, and David M. Dilts
See commentary p. 5381

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
Charles Comins, James Spicer, Andrew Protheroe, Victoria Roulstone, Katie Twigger, Christine M. White, Richard Vile, Alan Melcher, Matt C. Coffey, Karl L. Mettinger, Gerard Nuovo, David E. Cohn, Mitch Phelps, Kevin J. Harrington, and Hardev S. Pandha

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
D. Ross Camidge, Scott A. Kono, Antonella Flacco, Aik-Choon Tan, Robert C. Doebele, Qing Zhou, Lucio Crino, Wilbur A. Franklin, and Marielle Varella-Garcia

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients
Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, and Heinz-Josef Lenz

ABOUT THE COVER
Atu027, a liposomal siRNA, is a novel RNAi therapeutic for cancer therapy suppressing PKN3 gene expression in endothelial cells of the vasculature. In cultured human endothelial cells (HUVEC), Atu027 mediated downregulation of PKN3 led to increased levels of the adhesion protein vascular endothelial (VE)-cadherin. The different levels of VE-cadherin protein are depicted in this image in a color-coded manner reflecting highest VE-cadherin levels as red colored membrane staining. The authors show that Atu027 treatment modulates the vascular endothelium in a way that metastasis through the blood vessels to the lung is effectively inhibited. For further details, please see Santel and colleagues on page 5469 in this issue.
Clinical Cancer Research

16 (22)

Clin Cancer Res 2010;16:5369-5602.

Updated version Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/22

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.